Posted by Michael Wonder on 08 Apr 2026
PHARMAC funds medicine to reduce complications following allogenic haematopoietic stem cell transplant
8 April 2026 - People with very weak immune systems, including those recovering from an allogenic haematopoietic stem cell transplantation, will be better protected from a serious viral infection following PHARMAC’s decision to fund letermovir.
From 1 May 2026, PHARMAC will fund letermovir, a medicine that helps prevent cytomegalovirus infection in people who are severely immunosuppressed.
